Shineco Acquires 75% Stake in FuWang for $8.8 Million
By ATTN Desk · Editorial oversight: Sean Han
SHINECO INC (NASDAQ: SISI)
Company Overview
Shineco Inc. (샤인코) is a holding company incorporated in Delaware in August 1997 and headquartered in Beijing, China. Operating through subsidiaries and variable interest entities, Shineco develops, manufactures, and sells diagnostic medical products, related devices, and plant-based health and nutrition offerings.
Corporate Structure & Leadership
- Headquarters: Beijing, China
- Incorporated: Delaware, August 1997
- Subsidiaries & Affiliates:
- Changzhou Biowin Pharmaceutical Co., Ltd.
- Shineco Life Science Group Hong Kong Co., Ltd.
- Executive: Jennifer Zhan, Chief Executive Officer
- Employee Count: Not publicly disclosed
Recent Developments
March 25, 2025 – Acquisition of FuWang (HK) International Company Limited
- Equity Stake: 75% acquired via Shineco Life Science Group Hong Kong Co., Ltd.
- Consideration: Approximately US$ 8.8 million in cash, 3.4 million common shares, and the transfer of a 71.42% interest in Dream Partner Limited.
- Target Focus: Research and development (R&D) and commercialization of Class II and III medical devices, including biochemical analyzers, patient monitors, and mobile imaging workstations.
- Geographic Reach: Strong sales presence in Gansu, Henan, Jiangsu, and Shanxi provinces.
- Guidance from Seller:
- Projected Revenue: US$ 11.03 million (2025), US$ 13.79 million (2026), US$ 17.24 million (2027).
- Projected Net Profit: US$ 1.10 million (2025), US$ 1.38 million (2026), US$ 1.72 million (2027).
May 15, 2025 – Form 10-Q Filing
- Quarterly report filed with the SEC (CIK 0001300734) covering Q1 2025.
- Detailed financial statements and management discussion and analysis (MD&A) sections are available via EDGAR (form10-q.htm).
Financial & Strategic Analysis
| Metric | Value |
|---|---|
| Stock Price (2025-05-30) | US$ 0.4416 |
| Price Change (%) | –37.18% |
| Volume | 1,133,844 shares |
| Market Capitalization | US$ 14.58 million |
| 52-Week Range | US$ 0.3890 – 117.6480 |
| Price/Sales (TTM) | 0.03 |
| Price/Book (MRQ) | 0.80 |
| Profit Margin | 0.0% |
| Return on Assets (TTM) | –9.81% |
| Return on Equity (TTM) | –82.95% |
| Revenue (TTM) | US$ 9.6 million |
| Net Income (TTM) | –US$ 27.35 million |
| Total Cash (MRQ) | US$ 192,740 |
| Total Debt/Equity (MRQ) | 45.28% |
| Levered Free Cash Flow (TTM) | US$ 7.67 million |
- Valuation: At 0.03 × Price/Sales, the equity is trading at a low multiple relative to sales amidst ongoing net losses and negative returns.
- Cash Position: Limited cash reserves (US$ 192,740) and moderate leverage (45% debt/equity).
- Free Cash Flow: Positive levered free cash flow supports operational funding despite reported net losses.
- Strategic Moves: The FuWang acquisition is intended to create synergies in medical devices and expand R&D capabilities.
Market Position & Industry Context
- Core Markets: China (domestic sales of 5 product series and exports of 10 series), Europe (EU CE–certified), Australia, Spain, Thailand, and Japan.
- Sector: Point-of-care testing (POCT), in vitro diagnostics, and plant-based health products.
- Competitive Landscape: Competes with established global players in diagnostics and emerging domestic competitors in POCT.
- Growth Drivers: Demand for rapid diagnostics, integrated health-management networks, and preventive care is expected to drive growth in the industry.
tl;dr
- On March 25, 2025, Shineco acquired a 75% stake in FuWang (HK) for approximately US$ 8.8 million along with stock and asset transfers; FuWang projects US$ 11.03 million in revenue and US$ 1.10 million in net profit for 2025.
- As of May 30, 2025, the stock is priced at US$ 0.4416 (−37.18%), with a market cap of US$ 14.58 million, TTM revenue of US$ 9.6 million, and a net loss of US$ 27.35 million.
- The company operates a vertically integrated POCT and diagnostics business through subsidiaries in China and abroad, holding multiple device registrations and certifications.
- Recent SEC filings include a 10-Q for Q1 2025 (filed May 15) detailing financials and an amended 8-K (filed May 15). Future performance is contingent on the integration of FuWang operations and scaling of POCT product sales.